TNFSF4 and glioblastoma: Several other clinical trials in adult patients with recurrent glioblastoma/glioma are ongoing, such as a phase I/II trial of the vaccinia-based OV TG6002 combined with 5-FC (ONCOVIRAC, NCT03294486); a phase I trial of the adenoviral bases OV DNX-2440 expressing the immunostimulatory OX40 ligand (OX40-L) (NCT03714334); a phase I trial of a genetically engineered herpes simplex virus (HSV-1) expressing IL-12 named M032 (NCT02062827); and a phase I trial of a genetically engineered HSV-1, rQNestin34.5v.2, combined with cyclophosphamide (NCT03152318).